Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1997-09-09
2001-02-13
Jones, W. Gary (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200
Reexamination Certificate
active
06187533
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields diabetes. More particularly, it concerns the identification of genes responsible for diabetes for use in diagnostics and therapeutics.
2. Description of Related Art
Diabetes is a major cause of health difficulties in the United States. Non-insulin-dependent diabetes mellitus (NIDDM also referred to as Type 2 diabetes) is a major public health disorder of glucose homeostasis affecting about 5% of the general population in the United States. The causes of the fasting hyperglycemia and/or glucose intolerance associated with this form of diabetes are not well understood.
Clinically, NIDDM is a heterogeneous disorder characterized by chronic hyperglycemia leading to progressive micro- and macrovascular lesions in the cardiovascular, renal and visual systems as well as diabetic neuropathy. For these reasons, the disease may be associated with early morbidity and mortality.
Subtypes of the NIDDM can be identified based at least to some degree on the time of onset of the symptoms. The principal type of NIDDM has on-set in mid-life or later. Early-onset NIDDM or maturity-onset diabetes of the young (MODY) shares many features with the more common form(s) of NIDDM whose onset occurs in mid-life. Maturity-onset diabetes of the young (MODY) is a form of non-insulin dependent (Type 2) diabetes mellitus (NIDDM) that is characterized by an early age at onset, usually before 25 years of age, and an autosomal dominant mode of inheritance (Fajans 1989). Except for these features, the clinical characteristics of patients with MODY are similar to those with the more common late-onset form(s) of NIDDM.
Although most forms of NIDDM do not exhibit simple Mendelian inheritance, the contribution of heredity to the development of NIDDM has been recognized for many years (Cammidge 1928) and the high degree of concordance of NIDDM in monozygotic twin pairs (Barnett et al. 1981) indicates that genetic factors play an important role in its development.
MODY is characterized by its early age of onset which is during childhood, adolescence or young adulthood and usually before the age of 25 years. It has a clear mode of inheritance being autosomal dominant. Further characteristics include high penetrance (of the symptomology), and availability of multigenerational pedigrees for genetic studies of NIDDM. MODY occurs worldwide and has been found to be a phenotypically and genetically heterogeneous disorder.
A number of genetically distinct forms of MODY have been identified. Genetic studies have shown tight linkage between MODY and DNA markers on chromosome 20, this being the location of the MODY1 gene (Bell et al., 1991; Cox et al., 1992). MODY2 is associated with mutations in the glucokinase gene (GCK) located on chromosome 7 (Froguel et al. 1992 and 1993). Recent linkage studies have shown the existence of a further form of MODY which has been termed MODY3 (Vaxillaire et al., 1995). MODY3 has been shown to be linked to chromosome 12 and is localized to a 5 cM region between markers D12S86 and D12S807/D12S820 of the chromosome (Menzel et al., 1995).
Although it is well established that MODY2 is associated with mutations in GCK there is still no information as to the identity of other MODY genes. There is a clear need to identify these genes and the mutations that result in diseased states. The identification of these genes and their products will facilitate a better understanding of the diseased states associated with mutations in these genes and has important implications in the diagnosis and therapy of MODY.
Since an understanding of the molecular basis of diabetes in general and MODY specifically may facilitate the development of new therapeutic strategies for the treatment of these disorders, studies are needed to identify diabetes-susceptibility genes associated with MODY. Moreover, methods of detecting individuals with a propensity to develop such diseases are needed. Where possible, the molecular mechanism underpinning the genetic lesion should be determined in order to allow diagnosis and specifically-directed therapy.
SUMMARY OF THE INVENTION
The present invention relates to the inventors discovery that the MODY3 locus is the HNF1&agr; gene, the MODY1 locus is the HNF4&agr; gene and the MODY4 locus is the HNF1&bgr; gene. The invention further relates to the discovery that analysis of mutations in the HNF1&agr;, HNF1&bgr; and HNF4&agr; genes can be diagnostic for diabetes. The invention also contemplates methods of treating diabetes in view of the fact that mutations in HNF1&agr;, HNF1,&bgr; and HNF4&agr; can cause diabetes.
In one embodiment, the invention contemplates methods for screening for diabetes mellitus. These methods comprise: obtaining sample nucleic acid from an animal; and analyzing the nucleic acids to detect a mutation in an HNF-encoding nucleic acid segment; wherein a mutation in the HNF-encoding nucleic acid segment is indicative of a propensity for non-insulin dependent diabetes.
In certain embodiments the HNF-encoding nucleic acid is an HNF1&agr;-encoding nucleic acid. In view of the inventor's discovery that the MODY3 locus is HNF1&agr;, a mutation in the HNF1&agr;-encoding nucleic acid is indicative of a propensity for diabetes. In some presently preferred embodiments, the HNF1&agr;-encoding nucleic acid is located on human chromosome 12q, which is the location site of the MODY3 locus. In other embodiments, the HNF-encoding nucleic acid is an HNF4&agr;-encoding nucleic acid. In view of the inventor's discovery that the MODY1 locus is HNF4&agr;, a mutation in the HNF4&agr;-encoding nucleic acid is indicative of a propensity for diabetes. In some presently preferred embodiments, the HNF4&agr;-encoding nucleic acid is located on human chromosome 20, which is the location of the MODY1 locus.
It is important to note that the terms NIDDM, MODY, MODY1, MODY3, and MODY4 are used to designate diabetes disease states, and the use of a particular such name may not always represent the same causation of that disease state. The inventors have discovered that mutations in HNF4&agr; can lead to a MODY1 disease state; however, not all mutations in HNF4&agr; that lead to diabetes might cause a “MODY1” disease state. Conversely, not all diabetes disease states brought about by a mutation in HNF4&agr; might be considered a MODY1 disease state. Therefore, Applicants prefer to use, in some cases, “HNF4&agr;-diabetes” to note any diabetic disease state brought on by a mutation or malfunction of HNF4&agr;, even those that do not exhibit all, or any, MODY1 disease states. Likewise, Applicants may use “HNF1&agr;-diabetes” and “HNF1&bgr;-diabetes” rather than “MODY3” and “MODY4”, respectively.
The nucleic acid to be analyzed can be either RNA or DNA. The nucleic acid can be analyzed in a whole tissue mount, a homogenate, or, preferably, isolated from tissue to be analyzed. In some preferred embodiments, the step of analyzing the HNF-encoding nucleic acid comprises sequencing of the HNF-encoding nucleic acid to obtain a sequence, the sequence may then be compared to a native nucleic acid sequence of HNF to determine a mutation. Such a native nucleic acid sequence of HNF1&agr; may have the sequence set forth in SEQ ID NO: 1. Such a native nucleic acid sequence of HNF4&agr; has a sequence set forth in SEQ ID NO:78.
The method allows for the diagnosis of almost any mutation, including, for example, point mutations, translocation mutations, deletion mutations, and insertion mutations. The method of analysis may comprise PCR, an RNase protection assay, an RFLP procedure, etc. Using this method, the inventors have diagnosed a variety of HNF1&agr; mutations, including those set forth in Table 8. In preferred embodiments mutations occur at codons 17, 7, 27, 55/56, 98, 131, 122, 142, 129, 131, 159, 171, 229, 241, 272, 288, 289, 291, 292, 273, 379, 401, 443, 447, 459, 487, 515, 519, 547, 548 or 620 of an HNF1&agr;-encoding nucleic acid, for example, having the sequence of SEQ ID NO:1. In other pref
Bell Graeme I.
Furuta Hiroto
Horikawa Yukio
Kaisaki Pamela J.
Menzel Stephan
ARCH Development Corporation
Fulbright & Jaworski
Jones W. Gary
Souaya Jehanne
LandOfFree
Mutations in the diabetes susceptibility genes hepatocyte... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutations in the diabetes susceptibility genes hepatocyte..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutations in the diabetes susceptibility genes hepatocyte... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2614609